December 17, 2011 - Disease Area News
Recent studies has shown that deficiency in the MBL complement pathway suggest a worse prognosis in paediatric oncology patients. During the chemotherapy complement deficient children had increased frequency or severity of inflammation.
Frakking FNJ et al: Mannose-binding lectin (MBL) as prognostic factor in paediatric oncology patients. Clin Exp Immunol 2011; 165: 51-59